A Long-term Study of HSK44459 Tablets in Participants With Bechet's Disease

Summary

This is a long-term extension study of HSK44459-202 in eligible participants who have completed the Week 12 visit of the originating Study HSK44459-202. The total duration of this study will be up to 56 weeks which will include a 52-week treatment period, and a 4-week safety follow-up period after the last study intervention administration. Safety will be assessed by the incidence and severity of adverse events during the study.

Timeline

Start

2025-07

Primary completion

2027-07

Completion

2027-07

Drugs

Indications